New trial
Phase I Trial of Anti-GARP CAR-T in Recurrent High-Grade Glioma
- Trial ID
- NCT06964737 on ClinicalTrials.gov
- Cancer type
- Glioma / Glioblastoma
- Published in
- New in Oncology - May 21, 2025
Ohio State is evaluating the safety, optimal dosing, and initial efficacy of anti-GARP CAR-T cell therapy in patients with recurrent grade III/IV gliomas through a treatment protocol that includes apheresis, surgery with CSF reservoir placement, and serial intracavitary infusions.
More in brain and CNS tumors
-
Trial result · Oct 15, 2026 · NCT04365374
Cesium-131 collagen “GammaTile” brachytherapy cuts surgical-bed recurrence vs post-op SRT in resected brain mets -
Trial result · Oct 15, 2026 · NCT03946527
Lanreotide (somatostatin analog) shows disease stabilization in advanced PPGL in a Phase 2 preprint -
New trial · Oct 15, 2026 · NCT07831772
REMIND feasibility study tests a single maintenance IMRT fraction after temozolomide-based treatment in glioblastoma -
New trial · Oct 15, 2026 · NCT07664176
Phase 1 nivolumab plus focused ultrasound and microbubbles tests blood-brain barrier opening in recurrent pediatric brain tumors -
New trial · Oct 15, 2026 · NCT07831369
Phase 2 VISTA combines valproic acid, irinotecan, and simvastatin for recurrent malignant glioma